<< Read Full Article
<< Read Full Article
Biogen, Celltech Say Crohn's Disease Drug Failed
Biogen(BGEN Quote) and partner Celltech(CLL Quote) said Tuesday that an experimental drug for Crohn's disease currently under development failed to meet the endpoint in two late-stage clinical trials.
Biogen shares were off 85 cents, or 2%, to $35.10 in early trading. Celltech shares slid l.44, or 10%, to $12.40. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,306.45 | 1,091.06 | 2,133.11 | 32.09 |
Oil *
79.09
|
|
DOWN
3.47
|
DOWN
0.43
|
DOWN
5.33
|
DOWN
0.22
|
10 Yr
3.21%
SPDR Gold
115.47
|
|
-0.03%
|
-0.04%
|
-0.25%
|
-0.68%
|
Data delayed 20 minutes |
Connect with TheStreet